Skip to main content

CORRECTION article

Front. Pharmacol., 27 September 2022
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1000887

Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition

This article is a correction to:

  1. Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition

    1. Read original article
Jianyu Liu&#x;Jianyu Liu1†Minghai Tang&#x;Minghai Tang1†Tao LiTao Li2Zhengying SuZhengying Su1Zejiang ZhuZejiang Zhu1Caixia DouCaixia Dou1Yan LiuYan Liu1Heying PeiHeying Pei1Jianhong YangJianhong Yang1Haoyu YeHaoyu Ye1Lijuan Chen Lijuan Chen1*
  • 1State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China
  • 2West China-Washington Mitochondria and Metabolism Center, Department of Anesthesiology, Laboratory of Anesthesiology and Translational Neuroscience Center, West China Hospital of Sichuan University, Chengdu, China

A Corrigendum on
Honokiol ameliorates post-myocardial infarction heart failure through Ucp3 mediated reactive oxygen species inhibition

by Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H and Chen L (2022). Front. Pharmacol. 13:811682. doi: 10.3389/fphar.2022.811682

In the published article, there was an error in the Funding statement. “This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017202).” The correct Funding statement appears below.

Funding

“This work was supported by National Key Programs of China during the 13th Five-Year Plan Period (2018ZX09711001-002-012) and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20001).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: heart failure, myocardial infarction, honokiol, reactive oxygen species, UCP3

Citation: Liu J, Tang M, Li T, Su Z, Zhu Z, Dou C, Liu Y, Pei H, Yang J, Ye H and Chen L (2022) Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition. Front. Pharmacol. 13:1000887. doi: 10.3389/fphar.2022.1000887

Received: 22 July 2022; Accepted: 17 August 2022;
Published: 27 September 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Liu, Tang, Li, Su, Zhu, Dou, Liu, Pei, Yang, Ye and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lijuan Chen, chenlijuan125@163.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.